Literature DB >> 18435334

The effect of Nd:YAG laser membranotomy and intravitreal tissue plasminogen activator with gas on massive diabetic premacular hemorrhage.

Jin Chung1, Young-Hoon Park, Young-Chun Lee.   

Abstract

BACKGROUND AND
OBJECTIVE: To investigate the combined therapeutic effects of Nd:YAG laser membranotomy and intravitreal tissue plasminogen activator (tPA) (Actilyse; Boehringer Ingelheim, Ingelheim, Germany) injection with perfluoropropane (C3F8, 100%) injection on massive diabetic premacular hemorrhage. PATIENTS AND METHODS: Nd:YAG laser membranotomy was performed on the hemorrhagic membrane of premacular hemorrhage, and tPA (25 microg/0.1 mL) was injected into the vitreous cavity of seven eyes with massive diabetic premacular hemorrhage. For each procedure 0.2 mL of C3F8 was also injected.
RESULTS: After the combined therapy, the patients recovered vision within 4 weeks and the hemorrhages were completely absorbed within 8 weeks. Visual acuity at the last follow-up visit improved to a mean of 10 logarithm of the minimum angle of resolution lines in all cases. There were no associated ophthalmic complications.
CONCLUSION: The combined therapy resulted in resolution of premacular hemorrhages with proliferative diabetic retinopathy and may allow for faster resolution of premacular hemorrhages and lessen the need for vitrectomy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18435334     DOI: 10.3928/15428877-20080301-06

Source DB:  PubMed          Journal:  Ophthalmic Surg Lasers Imaging        ISSN: 1542-8877


  3 in total

1.  Nd:YAG membranotomy for preretinal hemorrhage secondary to valsalva retinopathy.

Authors:  Oscar Kuruvilla; Metasebia Munie; Manthan Shah; Uday Desai; Joel A Miller; Michael D Ober
Journal:  Saudi J Ophthalmol       Date:  2014-02-28

2.  Diabetic retinopathy - An update.

Authors:  Abdulrahman A Alghadyan
Journal:  Saudi J Ophthalmol       Date:  2011-01-31

3.  Pharmacologic vitreolysis.

Authors:  Hossein Nazari; Mehdi Modarres-Zadeh; Arash Maleki
Journal:  J Ophthalmic Vis Res       Date:  2010-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.